Positron emission tomography (PET) imaging has emerged as an important clinical tool for cancer management, and specifically targeted radiopharmaceuticals play critical roles on PET molecular imaging. Solid cancers have highly complex and heterogeneous microenvironment, this review focused on those microenvironmental factors such as hypoxia, proliferation and perfusion and, accordingly, a novel test system for validation of current and novel targeted imaging radiopharmaceuticals. In this review, we have introduced the establishment of cancer and metastases models in nude mice, visualization of microenvironmental components of hypoxia, proliferation, perfusion, stroma and necrosis in cancers and metastases for establishing the microenvironment based model system, and validation of several radiopharmaceuticals such as 18
Introduction
Positron emission tomography (PET) imaging has emerged as an important clinical tool for cancer detection, staging, and monitoring response to therapy. Current radiopharmaceuticals such as 18 F-fluoro-2-deoxyglucose ( 18 F-FDG), 18 F-fluorothymidine ( 18 F-FLT) and 18 F-misonidasole ( 18 F-FMISO) are commonly used PET tracers for cancer management. However, no tracer is conclusively superior in the management of cancer. Serial PET scans have been used in clinical studies in patients [1] [2] [3] [4] [5] [6] [7] and preclinical researches in animal models [8] [9] [10] [11] [12] [13] [14] to study the uptake mechanism of the tracers. However, the results have been mixed. This is probably due to: 1) solid cancers have highly complex and heterogeneous microenvironment [15] [16] [17] , it is impossible to generate two individual tumors with the same or similar microenvironment components and, subsequently, to compare the radiopharmaceuticals uptake in different tumors; 2) temporal change of tumor microenvironment may occur in a very short of interval of natural growth process of cancer and metastases, serial PET scans where the same tumor is probed with different tracers, separated by some time interval, are also problematic [18] .
Accordingly, a novel test system is highly demand for validation of current and novel targeted radiopharmaceuticals for molecular imaging. It is established that solid cancers have highly complex and heterogeneous microenvironment [15] [16] [17] composed of viable cancer cells, stroma, necrosis and many other factors. Viable cancer cells are either hypoxic or well oxygenated [15, 16, 18, 19] , the distribution of proliferative cells are also heterogeneous [8, 10, [18] [19] [20] [21] . In this review, we focused on the discussion of hypoxia, proliferation and perfusion microenvironment factors of cancer and metastases in animal model and its usefulness in PET tracers validation. We initially introduced the generation of cancer and metastases models in nude mice, then characterization of hypoxia, proliferation, perfusion, stroma and necrosis in cancer and metastasis using histological/immunohistochemical techniques, and finally, the relationship of radiopharmaceuticals accumulation and microenvironmenttal factors [18] .
Animal Models of Cancers and Metastases
Models of disseminated microscopic malignant disease may be generated in the lung, bone, liver and peritoneum by intravenous [22] [23] [24] , left ventricular [22, 25] , intrasplenic [26] and intraperitoneal [8, 18, 19, 27, 28] injection of tumor cells, respectively. We have shown that a model of disseminated microscopic peritoneal and ascites tumors was suitable for studying hypoxia [8, 18, 19, 27, 28] . In this model, disseminated peritoneal microscopic tumors were induced by injecting suspensions of colorectal HT29 and HCT-8 cancer cells, or non-small cell lung cancer (NSCLC) A549 and HTB177 cells into the peritoneal cavity of nude mice. Mice sacrificed 4 -7 weeks after tumor initiation displayed a distribution of tumors of sizes ranging from a few hundred micrometers up to several millimeters in diameter on or in the intestinal serosa (Figure 1) . Ascites fluid containing a distribution of free-floating tumor cell aggregates of up to 1 mm in diameter was also present in mice inoculated with HT29, A549 cells, but was not observed in HCT-8 and HTB177 cell lines. Intradermal injection of similar tumor cell suspensions could give rise to unitary microscopic tumors useful for studying hypoxia [8, 19, 27] . An intradermal tumor model has the potential advantage that growth curves for microscopic tumors could be more easily generated via ultrasound or optical imaging. Subcutaneous xenografts generated by subcutaneously injection of cancer cells are widely used for microPET study.
Tumor Microenvironment

Visualization of Hypoxia, Proliferation, Perfusion and Vasculature
Hypoxia microenvironment visualization relies on the detection of either exogenous substances (tracers) that preferentially localizes in hypoxic tissue or the expression of hypoxia-induced endogenous markers [28] . The most commonly used exogenous hypoxia markers, including pimonidazole, EF5 and CCI-103F, are 2-nitroimidazole compounds that are selectively reduced in hypoxic regions (generally pO 2 < 10 mmHg) of tumors, subsequently binding to intracellular macromolecules [28, 29] . The spatial pattern of binding of these markers can be visualized on tumor sections by immunohistochemical methods. Exogenous hypoxia markers have been widely used in clinical and experimental studies of tumor hypoxia [30] [31] [32] [33] . Pimonidazole is used to visualize tumor hypoxia in our group, which is generally administrated 1-2 hours before animal sacrifice. A large number of cellular proteins are regulated by hypoxia. Potential endogenous markers of hypoxia include hypoxia inducible factor 1α (HIF1α), carbonic anhydrase 9 (CA9) [19] and glucose transporters 1 (GLUT1) [8, 28] . The degradation of CA9 is a relatively slow process with estimated half-times of a few days [19] which would more appropriately indicate "historical" hypoxia. Thus combinations of endogenous protein markers used in conjunction with exogenous tracers can be used to detect changes in tumor hypoxia. Such an approach may be used to monitor the effect of interventions that perturb the intratumoral distribution of hypoxia [8, 19] .
The cellular proliferation marker bromodeoxyuridine was administered via tail vein injection 1hr before animal sacrifice to detect proliferative cancer cells [8, 18, 19] . Vasculature was visualized by Anti-CD31 staining [19, 28] . Perfusion was detected by fluorescent dye Hoechst 33342 which was administered via tail vein injection 1 minute before animal sacrifice [19] . Hematoxylin and eosin (H&E) provided information of viable cancer cells, stroma and necrosis with the tumor section. ritoneal inoculation of tumor cells. At the time of assay the gross appearance of peritoneal disease was similar for both cell lines, consisting of a distribution of small tumors adhering to the intestinal serosa [8, 19, 28] . Tumor sizes ranged from a few hundred μm to several mm in diameter. Microscopic examination of peritoneal tumor sections indicated a characteristic relationship between the pattern of hypoxia and tumor size. In general, submillimeter tumor deposits (<~1 mm diameter) showed intense pimonidazole staining coupled with low Hoechst 33342 staining (Figure 2(a) ). This observation was indicative of hypoxic and relatively poorly perfused tumors. Larger tumors (~1 -4 mm diameter) appeared relatively well perfused with generally low levels of pimonidazole staining. Anti-CD31 staining (Figure 2a ) showed a contrast in tumor vascularity between the tumors of different size with the smallest tumors possessing little to no vasculature while larger tumors were well-vascularized. bromodeoxyuridine staining indicated that cellular proliferation tended to occur in the rim but not the interior of small avascular tumors (Figure 2(b) ) whereas it was prevalent throughout larger tumors [8, 19, 28] . 
Hypoxia, Proliferation, Perfusion in Microscopic Intradermal Tumors
The patterns of hypoxia in intradermal tumors, ranging from a few hundred μm to several millimeters in diameter, were examined. Smaller intradermal tumors (<1 mm in diameter) were characterized by a high level of pimonidazole positivity and little to no visible Hoechst 33342 or CD31 positivity (Figure 2(c) ). In HT29 tumors, positive CA9 staining co-localized with pimonidazole. It was also observed that small intradermal tumors generally contained significant central necrosis. In contrast, for larger intradermal tumors (~1 -4 mm in diameter) pimonidazole staining appeared less intense, Hoechst 33342 was present throughout, together with significant vascularity and minimal necrosis (Figure 2 (c)) [19, 28] .
Hypoxia and Perfusion in Ascites Tumors
On microscopic examination HT29 ascites tumors appeared similar to small avascular HT29 peritoneal tumors of <1 mm in diameter (Figure 2(d) ). Ascites tumors stained intensely positive for pimonidazole and CA9 but negative for Hoechst 33342, indicating that they were mostly hypoxic with little to no blood perfusion [8, 19, 27] .
Microenvironment of Macroscopic Subcutaneous Tumors
Macroscopic subcutaneous tumors have intermingled but clearly defined regions of non-cancer cell stroma, cancer cells and necrosis. from NSCLC HTB177 subcutaneous xenograft. Cancer cells were further divided into two subcategories according to oxygenation status and cellular proliferation (Figure 3(b) ): cancer cells closely adjacent to functional blood vessels (positive Hoechst 33342 staining) were stained negative for pimonidazole but positive for bromodeoxyuridine, indicating well oxygenated and highly proliferative. Cancer cells located approximately 150 μm away from functional blood vessels and/or close to necrosis were stained positive for pimonidazole but negative for bromodeoxyuridine, which indicated that these cancer cells were hypoxic with low proliferation rate [18] .
Apparently, macroscopic solid cancers have complex microenvironment.
Relationship between Hypoxia and Tumor Size
The pimonidazole positive fraction (PPF) was estimated for a range of non-ascites HT29 tumors of various sizes (Figure 4 ) [19] . This reveals an interesting size-dependcy of tumor hypoxia. For the smallest peritoneal and intradermal tumors PPF was very high, approaching ~90% in tumors of several hundred μm diameter. At these sizes, tumors were relatively avascular. As peritoneal and intradermal tumors increased in size, the PPF decreased until in the range of diameters ~1 -4 mm there was little to no positive pimonidazole staining, indicating little to no tumor hypoxia, coupled with the appearance of tumor vascularization and significant blood perfusion. As tumor size increased further into the diameter range ≥~4 mm, positive pimonidazole staining reappeared in a characteristically perinecrotic distribution pattern that was inversely correlated with Hoechst 33342-defined perfusion.
We have visualized hypoxia, proliferation and perfusion in cancer and metastases models. The microenvironment-based model system has been used to validate and test several current PET tracers for imaging glucose metabolism, hypoxia and proliferation by our group [8, 18, 27] .
Examine Radiopharmaceuticals Using the Characterized Model System
Such model system may provide a useful means of corroborating the validity of purported targeted tracers. There are powerful methods of assessing the microenvi- ronmental features of individual microscopic tumors, including their hypoxic status, proliferation and blood perfusion, and relating these to the uptake of radiolabeled tracer. In addition, such models provide a diversity of tumors of differing size and hypoxic status growing in the same animal, thereby reducing or eliminating issues associated with inter-animal variability. To complement the high spatial resolution associated with immunohistochemical detection of hypoxia markers, the intratumoral distribution of radiolabeled hypoxia tracers can be determined by DAR detection systems. Studies comparing the spatial distributions of radiolabeled tracers and hypoxia markers have been reported in macroscopic tumors [10, 18, 34] and microscopic diseases [8, 18, 27] .
18 F-FDG
18
F-FDG PET has emerged as an important clinical tool for cancer detection, staging, and monitoring of response and is routinely used in the clinical management of several cancer types [35] . The uptake of 18 F-FDG, an analog of glucose, is largely proportional to the rate of glucose metabolism enabling this parameter to be quantified [36] . In hypoxic conditions, cancer cells may undergo a switch from aerobic to anaerobic glucose metabolism. This adaptive response involves the coordinated expression of many hypoxia inducible factor (HIF)-regulated proteins, such as GLUT-1, and various glycolytic enzymes [37] . Glucose metabolism in hypoxic cancer cells has been studied in cell culture and in animal models of macroscopic tumors (reviewed in [36] ), however, results have been mixed and controversial.
We have recently reported the use of correlative imaging methodologies to examine the uptake of 18 F-FDG in microscopic [8] and macroscopic [18] tumors and relate this to hypoxic status. 18 F-FDG uptake by DAR was compared with immunofluorescent visualization of pimonidazole binding and GLUT-1 expression. We have also reported that 18 F-FDG uptake in microscopic tumors was altered by carbogen breathing [8] . 18 F-FDG uptake in disseminated peritoneal disease arising from HT29, HCT-8, A549 and HTB177 tumor cells was studied in air-breathing animals [8, 18] . As shown in Figure 5 , there was spatial co-localization between high levels of 18 F-FDG uptake, pimonidazole binding and GLUT-1 expression. Such regions tended to correspond to low levels of cellular proliferation and blood perfusion. In particular, the smallest tumor deposits (<~1 mm diameter) were hypoxic (as evidenced by high pimonidazole binding) and had high 18 F-FDG uptake. In these tumors GLUT-1 expression was high, bromodeoxyuridine staining was confined to the rim and blood perfusion was minimal. Larger tumors (~1 -4 mm diameter) were not hypoxic (low pimonidazole binding) and displayed relatively low 18 F-FDG uptake and GLUT-1 expression. Additionally, bromodeoxyuridine-positive proliferative cells were distributed throughout the larger tumors and blood perfusion was relatively high. Carbogen breathing significantly decreased 18 F-FDG accumulation and tumor hypoxia in microscopic tumors but had little effect on GLUT1 expression (Figure 6 ) [8] . 18 F-FDG uptake in subcutaneous xenografts was also observed. High 18 F-FDG uptake was found in hypoxic zones but low 18 F-FDG uptake in well perfused cancer cells, non-cancerous stroma and necrosis (Figure 7 ) [18] .
Therefore, 18 F-FDG uptake was significantly increased in microscopic tumors and only hypoxic regions of macroscopic tumors. This enhanced uptake could be abrogated by carbogen breathing; physiological hypoxia was a necessary condition for increased 18 F-FDG uptake. expression in a small (~1 mm dimension) and relatively large tumor obtained from an animal with disseminated colorectal cancer HT29 peritoneal disease [27] : the smaller I-IAZGP uptake and low levels of pimonidazole binding and CA9 expression together with significant Hoechst 33342 uptake indicating that the tumor was wellperfused. Microscopic ascites tumors had high 131 I-IAZGP up-take coupled with intense staining of pimonidazole and CA9 (Figure 9 ) [27] .
Radioiodine-Labeled-Iodoazomycin
131
I-IAZGP uptake was also tested in intradermal tumors [27] . The smaller tumor (<1 mm in diameter) was characterized by a central lack of blood perfusion, high levels of co-localized pimonidazole binding and CA9 expression and high 131 I-IAZGP accumulation. In contrast, intradermal tumors above 1 mm in diameter were well perfused, had low 131 I-IAZGP and pimonidazole accumulation and had low CA9 expression (Figure 10) .
Intratumoral distribution of in subcutaneous xenografts and peritoneal tumors of NSCLC. High levels of 18 F-FMISO uptake and pimonidazole binding were colocalized [18] . Such regions tended to correspond to low levels of cellular proliferation and blood perfusion. Well oxygenated cancer cells with a high proliferation rate had low 18 F-FMISO uptake. Stroma and necrotic zones had lower 18 F-FMISO accumulation (Figure 11 ) [18] . We have validated that 131 I-IAZGP and 18 F-FMISO as hypoxia imaging tracers in colorectal and NSCLC microscopic and macroscopic tumor models, in which tumor microenvironment was characterized by immunohistochemical staining. Therefore, this model system is useful for validating current and novel hypoxia-imaging tracers.
18 F-FLT
18 F-FLT PET has been used to assess proliferation in cancer. We have used 18 F-FLT to test our model system [18] . 18 F-FLT preferentially accumulated in areas of tumor that showed high uptake of bromodeoxyuridine and low staining of pimonidazole. This was demonstrated for NSCLC cell lines A549 and HTB177, grown as either subcutaneous xenografts or disseminated peritoneal disease. For example, in HTB177 peritoneal tumors ( Figure  12 ), high 18 F-FLT uptake was found in the regions with high levels of bromodeoxyuridine binding (proliferative) cancer cells where pimonidazole stained negatively indicating well oxygenated. Low 18 F-FLT accumulation was found in cancer cells which were stained positive for pimonidzole (hypoxia) but low for bromodeoxyuridine (low proliferation). Stroma and necrotic zones also associated with low 18 F-FLT accumulation.
18
F-FLT uptake significantly correlated with proliferation index (r = 0.91, p < 0.001) [18] . Therefore, our model system enables to validate current and novel tracers imaging proliferation. 
The Importance of Animal Models of Metastases for Novel Targeted Radiopharmaceuticals Development
Animal models of metastases as a test system for radiotracer validation have several advantages compared with macroscopic subcutaneous xenografts. Individual small tumors have an approximately homogenous internal structure, being either hypoxic and unperfused, or non-hypoxic and well perfused. This makes it relatively simple to demonstrate co-localization of radiotracer and hypoxia marker (immunofluorescence). In contrast, macroscopic xenografts have a complex internal structure with intermingled regions of non-cancerous stroma, well oxygenated tumor, hypoxia and necrosis in close proximity. Another advantage is that since many tumors of various sizes and degrees of hypoxia can exist in an individual animal, it is possible to compare radiotracer uptake between tumors without confounding variations due to dif- ferences in injected dose or inter-animal pharmacokinetics [8, 18, 27] . Therefore, metastatic model is a valuable supplement to macroscopic xenograft models as a test system for novel molecular imaging tracer development. It should be emphasized here that macroscopic xenograft model is still very important in PET studies. There are some limitations for using autoradiograph and immunohistochemical staining techniques to study tumor hypoxia. Hypoxia can be chronic (perfusion limited) hypoxia or acute hypoxia (transient hypoxia, or diffusion-limited"). To some extent, immunohistochemical staining of hypoxia marker seems to be unable to distinguish chronic hypoxia from acute hypoxia, therefore a general term "hypoxia" is used throughout the article; Transient hypoxia is observed to be an important factor for radiotherapy resistance and is difficult to figure out, Wang and colleagues have recently established a model to successfully identify hypoxia with dynamic PET scan [44] .
Conclusion
This review has introduced the establishment of cancer and metastases models and characterization of tumor microenvironment including hypoxia, proliferation, perfusion, stroma in the experimental tumors. The microenvironment-based model system enables to validate several radiopharmaceuticals such as 18 F-FLT. This model system would be useful for validating current and, therefore, novel tracers imaging glucose metabolism, hypoxia, proliferation and possibly others.
